Table 1

Inclusion and exclusion criteria of the PINPOINT study

Inclusion criteriaExclusion criteria
  • Provision of informed consent prior to any study-specific procedure

  • Treatment with ticlopidine, clopidogrel, prasugrel or ticagrelor within 14 days before the study enrolment

  • Diagnosis of STEMI or NSTEMI

  • Hypersensitivity to ticagrelor

  • Men or non-pregnant women

  • Current treatment with oral anticoagulant or chronic therapy with low-molecular-weight heparin

  • Provision of informed consent for angiography and PCI

  • Active bleeding

  • History of intracranial haemorrhage

  • Fibrinolytic treatment during the index event

  • Recent gastrointestinal bleeding (within 30 days)

  • History of coagulation disorders

  • History of moderate or severe hepatic impairment

  • History of major surgery or severe trauma (within 3 months)

  • Second or third degree atrioventricular block during screening for eligibility

  • Patient requiring dialysis

  • Manifest infection or inflammatory state

  • Killip class III or IV during screening for eligibility

  • Respiratory failure

  • Current therapy with strong CYP3A inhibitors or strong CYP3A inducers

  • NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.